Legacy processes can't scale to meet growing demand - GemBio is building a platform for mass adoption
What does the future of therapeutics look like?
At GemBio, we believe the future lies in oligonucleotide therapies, and we're building a reimagined manufacturing process to power it.
GemBio’s manufacturing platform is built for scalability, delivering greater production capacity than conventional methods to enable more doses per year and reduce manufacturing bottlenecks.
Powered by our proprietary ClarityCapture™ technology, the platform introduces a cleavable purification tag that enables resin-free isolation of the target oligonucleotide. Paired with our optimized synthesis method, it delivers high-purity oligonucleotides and consistent CMC profiles at every scale.
We partner closely with therapeutic developers to reduce clinical translation risks and accelerate their path to the clinic.
